[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599940":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":38,"centralContacts":42,"locations":48,"responsibleParty":259,"collaborators":10,"id":261,"slug":262,"hasResults":263,"nctId":264,"briefTitle":265,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":263,"sex":268,"minAge":269,"maxAge":270,"enrollmentInfo":271,"targetDuration":274,"studyType":275,"phases":10,"briefSummary":276,"conditions":277,"keywords":279,"overallStatus":51,"whyStopped":10,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":309},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8,14,18,22,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Asciminib",null,"Patients who started their 1L or 2L asciminib following FDA approval on or after Oct-2024 OR Patients who have exited an asciminib interventional study in US for 1L\u002F2L CML and are continuing treatment with asciminib in routine medical care",[13],"Other: TKIs",{"label":15,"type":10,"description":16,"interventionNames":17},"Bosutinib","Patients who started 1L or 2L bosutinib on or after Oct-2021",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Dasatinib","Patients who started 1L or 2L dasatinib on or after Oct-2021",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Imatinib","Patients who started 1L or 2L imatinib on or after Oct-2021",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Nilotinib","Patients who started 1L or 2L nilotinib on or after Oct-2021",[13],[31],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"OTHER","TKIs","There is no treatment allocation for NIS trials. Patients administered TKI (asciminib, bosutinib, dasatinib, imatinib, nilotinib) by prescription will be enrolled.",[9,15,19,23,27],[37],"Scemblix, Bosulif, Sprycel, Gleevec, Tasigna",[39],{"name":40,"affiliation":40,"role":41},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[43,47],{"name":40,"role":44,"phone":45,"phoneExt":10,"email":46},"CONTACT","1-888-669-6682","novartis.email@novartis.com",{"name":40,"role":44,"phone":10,"phoneExt":10,"email":10},[49,69,84,96,109,124,139,152,164,177,190,205,220,235,249],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"University of Alabama at Birmingham","RECRUITING","Birmingham","Alabama","35233-0271","United States","US",{"type":58,"coordinates":59},"Point",[60,61],-86.80249,33.52066,{"lat":61,"lon":60},[64,66],{"name":10,"role":44,"phone":65,"phoneExt":10,"email":10},"+1 205 502 9967",{"name":67,"role":68,"phone":10,"phoneExt":10,"email":10},"Omer Jamy","PRINCIPAL_INVESTIGATOR",{"facility":70,"status":51,"city":71,"state":72,"zip":73,"country":55,"countryCode":56,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Stockton Hematology Oncology Medical Group Inc","Stockton","California","95204",{"type":58,"coordinates":75},[76,77],-121.29078,37.9577,{"lat":77,"lon":76},[80,82],{"name":10,"role":44,"phone":81,"phoneExt":10,"email":10},"+1 209 466 2626",{"name":83,"role":68,"phone":10,"phoneExt":10,"email":10},"Ravleen Grewal",{"facility":85,"status":51,"city":86,"state":72,"zip":87,"country":55,"countryCode":56,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"Lundquist Inst BioMed at Harbor","Torrance","90509-2910",{"type":58,"coordinates":89},[90,91],-118.34063,33.83585,{"lat":91,"lon":90},[94],{"name":95,"role":68,"phone":10,"phoneExt":10,"email":10},"Sarah Elizabeth Tomassetti",{"facility":97,"status":51,"city":98,"state":99,"zip":100,"country":55,"countryCode":56,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"Stamford Hospital","Stamford","Connecticut","06902",{"type":58,"coordinates":102},[103,104],-73.53873,41.05343,{"lat":104,"lon":103},[107],{"name":108,"role":68,"phone":10,"phoneExt":10,"email":10},"Joshua Dower",{"facility":110,"status":51,"city":111,"state":112,"zip":113,"country":55,"countryCode":56,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"Sacred Heart Medical Oncology","Pensacola","Florida","32504",{"type":58,"coordinates":115},[116,117],-87.21691,30.42131,{"lat":117,"lon":116},[120,122],{"name":10,"role":44,"phone":121,"phoneExt":10,"email":10},"+1 850 416 2730",{"name":123,"role":68,"phone":10,"phoneExt":10,"email":10},"Dany El-Sayah",{"facility":125,"status":51,"city":126,"state":127,"zip":128,"country":55,"countryCode":56,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"St Agnes Hospital","Baltimore","Maryland","21229",{"type":58,"coordinates":130},[131,132],-76.61219,39.29038,{"lat":132,"lon":131},[135,137],{"name":10,"role":44,"phone":136,"phoneExt":10,"email":10},"+1 410 368 3412",{"name":138,"role":68,"phone":10,"phoneExt":10,"email":10},"Carole Miller",{"facility":140,"status":51,"city":141,"state":142,"zip":143,"country":55,"countryCode":56,"cosmosGeoPoint":144,"geoPoint":148,"contacts":149},"NY Cancer and Blood Specialists","East Setauket","New York","11733",{"type":58,"coordinates":145},[146,147],-73.10594,40.94149,{"lat":147,"lon":146},[150],{"name":151,"role":68,"phone":10,"phoneExt":10,"email":10},"Adam Hines",{"facility":153,"status":51,"city":154,"state":142,"zip":155,"country":55,"countryCode":56,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"SUNY Upstate Medical University","Syracuse","13210",{"type":58,"coordinates":157},[158,159],-76.14742,43.04812,{"lat":159,"lon":158},[162],{"name":163,"role":68,"phone":10,"phoneExt":10,"email":10},"Gillian Kupakuwana-Suk",{"facility":165,"status":51,"city":166,"state":167,"zip":168,"country":55,"countryCode":56,"cosmosGeoPoint":169,"geoPoint":173,"contacts":174},"Tri-County Hematology and Oncology Associates","Canton","Ohio","44718",{"type":58,"coordinates":170},[171,172],-81.37845,40.79895,{"lat":172,"lon":171},[175],{"name":176,"role":68,"phone":10,"phoneExt":10,"email":10},"Norman Rafique",{"facility":178,"status":51,"city":179,"state":180,"zip":181,"country":55,"countryCode":56,"cosmosGeoPoint":182,"geoPoint":186,"contacts":187},"Oregon Oncology Specialists Salem","Salem","Oregon","97301",{"type":58,"coordinates":183},[184,185],-123.0351,44.9429,{"lat":185,"lon":184},[188],{"name":189,"role":68,"phone":10,"phoneExt":10,"email":10},"John Strother",{"facility":191,"status":51,"city":192,"state":193,"zip":194,"country":55,"countryCode":56,"cosmosGeoPoint":195,"geoPoint":199,"contacts":200},"Avera Cancer","Sioux Falls","South Dakota","57105",{"type":58,"coordinates":196},[197,198],-96.72796,43.54369,{"lat":198,"lon":197},[201,203],{"name":10,"role":44,"phone":202,"phoneExt":10,"email":10},"+1 605 322 3064",{"name":204,"role":68,"phone":10,"phoneExt":10,"email":10},"Tiffani Kirkpatrick",{"facility":206,"status":51,"city":207,"state":208,"zip":209,"country":55,"countryCode":56,"cosmosGeoPoint":210,"geoPoint":214,"contacts":215},"Baylor Scott and White Research","Temple","Texas","76502",{"type":58,"coordinates":211},[212,213],-97.34278,31.09823,{"lat":213,"lon":212},[216,218],{"name":10,"role":44,"phone":217,"phoneExt":10,"email":10},"+1 254 935 5838",{"name":219,"role":68,"phone":10,"phoneExt":10,"email":10},"Lucas Wong",{"facility":221,"status":51,"city":222,"state":223,"zip":224,"country":55,"countryCode":56,"cosmosGeoPoint":225,"geoPoint":229,"contacts":230},"Fred Hutchinson Cancer Research Center","Seattle","Washington","98109-1024",{"type":58,"coordinates":226},[227,228],-122.33207,47.60621,{"lat":228,"lon":227},[231,233],{"name":10,"role":44,"phone":232,"phoneExt":10,"email":10},"+1 206 667 7315",{"name":234,"role":68,"phone":10,"phoneExt":10,"email":10},"Vivian Oehler",{"facility":236,"status":51,"city":237,"state":223,"zip":238,"country":55,"countryCode":56,"cosmosGeoPoint":239,"geoPoint":243,"contacts":244},"MultiCare Health System Institute","Tacoma","98405",{"type":58,"coordinates":240},[241,242],-122.44429,47.25288,{"lat":242,"lon":241},[245,247],{"name":10,"role":44,"phone":246,"phoneExt":10,"email":10},"+1 253 403 5265",{"name":248,"role":68,"phone":10,"phoneExt":10,"email":10},"Nehal Masood",{"facility":250,"status":51,"city":237,"state":223,"zip":238,"country":55,"countryCode":56,"cosmosGeoPoint":251,"geoPoint":253,"contacts":254},"Northwest Medical Specialties",{"type":58,"coordinates":252},[241,242],{"lat":242,"lon":241},[255,257],{"name":10,"role":44,"phone":256,"phoneExt":10,"email":10},"+1 253 428 8756",{"name":258,"role":68,"phone":10,"phoneExt":10,"email":10},"Ali Dadla",{"type":260,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100599940","a-real-world-chronic-myelogenous-leukemia-cml-patient-disease-registry-to-describe-patient-experience-and-clinical-outcomes-among-patients-with-cml-receiving-approved-first-or-second-line-tyrosine-kinase-inhibitor-tki-therapy-100599940",false,"NCT07091019","A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy","ASC4REAL-2","Inclusion Criteria:\n\n* 18 years or older at the time of Ph+-CML-CP diagnosis.\n* Receiving TKI treatment (asciminib, bosutinib, dasatinib, imatinib, or nilotinib) in routine medical care either as initial therapy or after 1 prior TKI therapy.\n* Receiving treatment at US and US territories (i.e., Puerto Rico) medical practice (e.g. community-based, office-based, hospital-based, academic).\n* Signed informed consent form (ICF) prior to participation in the study including agreement to be tokenized so that the patient's anonymized RWD (EMRs and\u002For claims data) can be accessed.\n\nExclusion Criteria:\n\n* Active participation in an interventional trial that may influence the management of their Ph+-CML-CP disease.\n* Currently being treated with a CML TKI in 3L or beyond.\n* Known presence of T315I mutation.\n* Currently in TFR phase and are not on active CML TKI therapy.\n* Previously received treatment with a prior stem cell transplant\n* Pregnant or nursing (lactating) female.","ALL","18 Years","100 Years",{"count":272,"type":273},1000,"ESTIMATED","5 Years","OBSERVATIONAL","This CML disease registry (ASC4REAL-2) aims to gather evidence on the tolerability, safety, effectiveness, and patient-reported outcomes (PRO) in real-world healthcare from patients with Ph+-CML-CP treated with TKIs approved for 1L and 2L, including prospective follow-up for 5 years identifying and describing long-term treatment outcomes.",[278],"Chronic Myelogenous Leukemia - Chronic Phase",[280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299],"CML,","CMP-CP,","ASC4REAL,","ASC4REAL-2,","chronic phase,","BCR-ABL, MMR,","TKI,","Tyrosine Kinase Inhibitor,","molecular response,","adult,","registry,","PRO,","patient reported outcome,","QOL,","quality of life,","asciminib,","bosutinib,","imatinib,","nilotinib,","dasatinib","2026-06-22",{"date":302,"type":303},"2026-06-25","ACTUAL",{"date":305,"type":303},"2025-12-17",{"date":307,"type":273},"2033-04-20",{"name":40,"class":6},15]